Could a common acid blocker save transplanted kidneys?

NCT ID NCT07275632

Recruiting now Disease control Sponsor: First Affiliated Hospital of Chongqing Medical University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests whether a stomach acid drug called vonoprazan fumarate can reduce delayed graft function, a common complication where a new kidney doesn't work right away. About 47 first-time kidney transplant recipients will take the drug for seven days after surgery. Researchers will measure how many need dialysis and how well the kidney recovers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: vonoprazan fumarate
What this could lead to: If it works, this could point toward a simple, short-term treatment to help new kidneys work sooner after transplant, reducing the need for dialysis.
What could go wrong: This is a very early, small study (47 people) with no placebo group, so results may not be reliable. The drug may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DELAYED GRAFT FUNCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Delayed Graft Function end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DELAYED GRAFT FUNCTION KIDNEY TRANSPLANTATION

Contacts and locations

Locations

Sun Yat-sen Memorial Hospital, Sun Yat-sen University
NOT_YET_RECRUITING

Guangzhou, China
The First Affiliated Hospital of Chongqing Medical University
RECRUITING

Chongqing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.